Search results
Lilly's Alzheimer's drug faces delayed reckoning
Axios· 2 hours agoState of play: Lilly's antibody donanemab was shown to be effective in slowing Alzheimer's progression by about a third, and it could become the second ...
A Drug to Slow Alzheimer’s Is Finally Available. How Are Patients Faring?
New York Times· 5 hours agoLecanemab (brand name Leqembi) was given full approval by the Food and Drug Administration in July...
Supreme Court’s Strains Intensify as Term’s End Approaches
The Wall Street Journal· 1 day agoIdeological differences and ethical questions are testing the justices as they wrestle with ...
Eli Lilly Is Trading At A Record High Ahead Of A Key FDA Meeting — Is It A Buy?
Investor's Business Daily· 3 days agoThe decision effectively pushes back the approval decision, which was expected in the first quarter....
In review of Lilly Alzheimer’s drug, FDA staff focus on safety, patient selection
BioPharma Dive via Yahoo Finance· 4 days agoThe agency is seeking input from an advisory panel on whether donanemab is effective across...
Column: With Chicago Cubs in a familiar swoon, can they escape the summertime blues with another...
Chicago Tribune via Yahoo Sports· 3 hours agoSummer rerun season is upon us, which means Chicago baseball fans are being force-fed the same...
Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze
InvestorPlace· 3 days agoOne of the fastest ways to make money on the stock market is to gamble on short-term contrarian...
Psychoactive drugs are having a moment: The FDA will soon weigh in
Medical Xpress· 7 days agoRaised in New Orleans by a mother with untreated bipolar disorder who later killed herself and two...
Why the Supreme Court’s abortion pill ruling might not end legal fight
Washington Post· 6 days agoWhen the Supreme Court debated this spring whether to limit access to a widely used abortion...
Research shows GLP-1 receptor agonist drugs are effective but come with complex concerns
Medical Xpress· 6 days ago"The current fervor for GLP-1RAs in the capital markets as well as in the general public, especially in terms of weight reduction, is probably going to result in overuse," said Chun-Su Yuan, ...